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Abstract
Although natural antibodies (NAbs) are present from birth, little is known about what drives their
selection, and whether they have housekeeping functions. The prototypic T15-NAb, first identified
because of its protective role in infection, is representative of a special type of NAb response that
specifically recognizes and forms complexes with apoptotic cells, and which promotes cell-corpse
engulfment by phagocytes. We now show that this T15-NAb IgM-mediated clearance process is
dependent on the recruitment of C1q and mannose-binding lectin (MBL), which have known immune
modulatory activities that also provide “eat me” signals for enhancing phagocytosis. Further
investigation revealed that the addition of T15-NAb significantly suppressed in vitro LPS-induced
TNF-α and IL-6 secretion by the macrophage-like cell line, RAW264.7, as well as Toll-like receptor
(TLR)-induced maturation and secretion of a range of pro-inflammatory cytokines and chemokines
by bone-marrow derived conventional dendritic cells. Significantly, high doses of this B-1 cell
produced NAb also suppressed in vivo TLR–induced pro-inflammatory responses. While infusions
of apoptotic cells also suppressed such in vivo inflammatory responses and this effect was associated
with the induction of high levels of IgM anti-apoptotic cell antibodies, apoptotic cell treatment was
not effective at suppressing such TLR responses in B-cell deficient mice. Moreover, infusions of
T15-NAb also efficiently inhibited both collagen-induced arthritis and anti-collagen II antibody-
mediated arthritis. These studies identify and characterize a previously unknown regulatory circuit
by which a NAb product of innate-like B cells aids homeostasis by control of fundamental
inflammatory pathways.
To defend against infectious agents, yet also guard against autoimmune disease, complex
activating and inhibitory pathways have evolved that interconnect the innate and adaptive
immune systems and control their activation. The innate immune system senses for threats by
recognizing microbe-associated molecular motifs using limited sets of cellular receptors, such
as Toll-like receptors (TLRs), as well as soluble immune recognition opsonizing factors, such
as complement, collagen-like lectins (i.e., collectins) and C-reactive protein. Some of these
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receptors also bind to stress-associated proteins and other self-ligands (reviewed in (1)).
Professional phagocytic cells, macrophages (Mφ) and dendritic cells (DCs) thereby respond
to environmental stimuli, microbial antigens and cytokines, which by facilitating or forbidding
differentiation changes control the capacity of Mφ and DC for overall inflammatory responses
as well as the immunogenicity of foreign and self antigens.
While the innate immune system is important or even essential for modulating lymphocyte
responses, innate immune responses themselves are also reciprocally influenced by specialized
tiers of the adaptive immune system, such as natural killer (NK), NKT, and γδ T cells, which
can recruit DCs into pro-inflammatory responses (2). We have wondered how B lymphocytes
might also affect innate responses, especially by B-1 cells, the primordial tier of the B-
lymphocyte compartment that is the major source of the “non-immune” IgM NAbs
constitutively produced throughout life, and which are also involved in responses to non-
protein antigens (3). This distinct set of self-replenishing mature B lymphocyte have been
described as innate-like as they express a restricted and recurrent antibody repertoire that arises
by a programmed sequence during immune development (3,4). Indeed, certain B-1 cell clones
appear to have regulatory roles through effects on innate immune cells even at remote sites in
the body (5), although how this might occur is not known.
The prototypic T15 B-1 cell clonotype, defined by H-L puaired canonical antibody gene
rearrangements without hypermutation, was first characterized 40 years ago (6) with later
repeated independent isolations (e.g. S107 (7), HPCM2 (8), EO6 (9) and others). T15
clonotypic B cells spontaneously arise and become highly represented within the first week of
life, even in mice raised under germ-free conditions (10), which suggests that microbial ligands
are not primary mediators of clonal selection. It has long been known that T15-NAbs bind to
phosphorylcholine (PC) determinants, and contribute to host defense to PC-containing
pneumococci, and other microbes, and provide optimal protection from systemic infection
(11). More recently, PC-determinants were also identified on oxidatively-modified low density
lipoprotein (LDL) generated during atherogenesis (9). Significantly, pneumococcal
immunization, which induced active B-cell responses that raised T15 antibody levels, greatly
ameliorated the chronic inflammatory response in a murine model of hyperlipidemia and
atherosclerosis (12). The mechanistic basis for these findings remains obscure, as the original
hypothesis, that T15-NAb might enhance clearance of the pro-inflammatory oxidatively-
modified LDL, has subsequently been ruled out (13). While more recent studies suggest the
possibility that immunization may induce regulatory B-cells that serve as a source of inhibitory
cytokines (14), we have suspected there are other antibody-mediated immune modulatory
activities.
Other studies have previously shown that by immune recognition of the PC head group, T15-
NAb can discriminate dead/dying cells from healthy cells (15–17). This is because the PC-
head group, which is a ubiquitous component of cell membrane neutral phospholipids (e.g.
phosphatidylcholine), is embedded within the lipid bilayer in healthy cells and therefore
inaccessible to antibodies unless exposed by membrane changes that occur during apoptosis
(15–17). Importantly, we have shown that T15-NAb is structurally and functionally
representative of the PC-specific anti-apoptotic cell antibodies that are induced in vivo by
apoptotic cell infusions (18).
Herein, we show that the prototypic T15-NAb can play a general role in modulating innate
immune responses by inhibiting the activation of phagocytes, and thereby suppressing in vitro
and in vivo inflammatory responses. We further show that these regulatory properties derive
from the capacity to complex with apoptotic cells and recruit soluble innate immune
recognition molecules, which together enhance uptake and clearance of apoptotic cells and
inhibit TLR induced phagocyte activation and maturation.
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Materials and Methods
Antibodies
T15-IgM (from the EO6 hybridoma)(9), and the IgM isotype control from the hybridoma,
NC17-D8 (gift of L. Arnold, UNC, Chapel Hill NC), both express J-chain transcripts.
Hybridomas were grown under serum-free conditions in hollow fiber (10,000 MWCO)
bioreactors in Hybridoma Serum free media (Invitrogen, Carlsbad CA) to a cell density of
~5×108/ml) and then maintained for 30–45 days, by NCCC (Minneapolis, MN). Supernatants
were purified with a 300 kDa tangential flow filtration (TFF) device, followed by a 10kDa TFF
for further concentration, then dialyzed against PBS pH 7.2, with documented low endotoxin
(< 0.5 EU/mg), then aliquots stored at −80°C. By native PAGE analysis and western blot, the
predominant IgM populations were pentamers with <10% hexamers, without monomeric IgM
or low molecular weight species.
Antibody assays
Standard sandwich ELISA were performed with precoats of goat anti-IgM, PC-albumin for
control antigens, with detection with either biotinylated AB1-2 to detect T15-colonotypic
antibodies (19), or anti-IgM or anti-IgG, as described (20). Assays were adapted to buffer usage
required to detect MBL-binding, as described (21), with limits of detection of ~5 ng/ml. In
these studies MBL binding by IgG could not be detected in sera either before or after
thymocytes immunization. Array studies were performed as described (22).
Mice
Age and gender-matched adult C57BL/6, congenic B-cell deficient muMT, BALB/c and DBA/
1 mice were provided by The Jackson Laboratory (Bar Harbor, ME) or bred under SPF-
conditions as supervised by UCSD Animal Care Program. All animal protocols were approved
by the UCSD IACUC.
In vitro complement deposition
Apoptotic thymocytes were incubated at 37°C with IgM at 20 ug/ml in Tris-buffered saline
with 10 mM CaCl2, and/or Tris-buffered saline (TBS) with 20% Ig-deficient plasma for
complement or TBS alone. After 40min, cells were washed and studied for apoptosis (7AAD
and Annexin V), and with APC-labeled goat anti-IgM, and anti-C1q (goat, Cedarlane Labs),
or human recombinant MBL (6 ug/ml) and biotinylated mouse anti-human MBL (clone 131-1),
or biotinylated rat anti-murine MBL A (clone 2B4) anti-murine MBL C)(clone14D12)(21), in
the presence of Fc block (23).
In vivo apoptotic clearance assays
Using a standard in vivo approach (24), B-cell deficient mice received thioglycollate treatment
and 3d later received intravenous PBS or 1 mg of IgM. After 16 hr, 5 ×106 SNARF-1 labeled
apoptotic or fresh thymocytes were instilled, then peritoneal cells recovered after 10 min. For
immunofluorescence microscopic studies, cytospins were prepared and Mφ stained with FITC-
anti-F4/80, with >800 Mφ counted per mouse and the proportion determined of recovered
Mφ that had ingested (and not just surface bound) one or more labeled thymocytes. Although
longer time periods were also examined, 10 min of in vivo exposure yielded the greatest
differences between groups, as previously described (36). While dexamethasone-treated
thymocytes yielded similar results, most studies used etoposide for apoptosis induction due to
>95% Annexin V+ (i.e., apoptotic) thymocyte yields by flow cytometry. In other studies, to
quantitate Mφ uptake, flow cytometric analyses were performed with 7AAD and Annexin V
staining of apoptotic thymocytes that were tracked via CD3 (Becton-Dickinson), with
peritoneal Mφ detected with FITC-conjugated F4/80 (Caltag).
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RAW264.7 cell cultures
Cells were grown to 80% confluence with ~105 cells per well in 48 well plates in 48-well plates
in RPMI and 10% FBS, glutamine and 0.01 M Hepes, then serum starved overnight. To some
replicates were preincubated with T15 IgM or isotype control for 1 hr, followed by addition
of LPS (E. coli 055:B5, List Biological Labs) at 0.1 ug/ml or polyinosinic-cystidic acid (poly
I:C)(Amersham) at 3.3 ug/ml for overnight culture,
Bone-marrow derived dendritic cells
Bone marrow cells from C57BL/6 femurs/tibias were washed and cultured in RPMI containing
10% FBS 1% Pen-Strep-Glutamine, GM-CSF (10 ng/ml) and IL-4 (400 pg/ml), replenished
on d3 (25). On day 6, DC were selected in the presence of Fc block with magnetic anti-CD11c
beads using LS magnetic columns (Milltenyi) to >94% CD11c+ purity. For phagocytosis
assays, DC were cultured with GM-CSF but without IL-4 and harvested on day 5 CD11c+ cells
were purified, then cultured at 0.5 × 106/100 ul in 96 well plates overnight in a 1:1 ratio with
CFSE labeled healthy or etoposide-induced apoptotic cells, as described (18). Some studies
instead used STEMSPAN SF Expansion (Stem Cell Technologies) serum-free media. For heat
inactivation, Ig-deficient sera were incubated for 30 min at 56°C.
For stimulation studies, DC were further cultured for 24–48 hrs without/with agonists for
TLR3, (polyinosinic:polycytidylic acid, poly I:C) at 3.3 ug/ml; TLR4, LPS at 0.1 ug/ml; TLR7,
imiquimod (Invivogen) at 1 ug/ml; or TLR9, phosphorothioate CpG oligo 1018 at 0.5 ug/ml.
Replicate cultures included serial concentrations of T15-IgM or IgM-isotype control. Other
cultures included blocking antibody to IL-10 or isotype control (R&D Systems) with Fc block,
as per manufacturer’s directions. Cultures with T15-NAb blockade with AB1-2 anti-idiotype
or isotype control also included Fc block. To assess DC maturation, cells were co-stained with
PE- anti-mouse CD80 (clone 16-10A1) and for intra-cellular Alexa-Fluor 647 anti-IL-12 p40
(clone C17-8), as per manufacturer’s protocol (eBiosciences). QPCR was performed as
previously described (20).
DC isolation
Splenic DC were isolated, as reported (25), then evaluated by flow cytometry for defined DC
subsets and maturation/activation markers. Transcript analysis after 6 hr of in vitro stimulation
of CD11c-enriched BM-derived DC were performed by Taqman (Applied Biosystems), using
manufacturer’s directions.
In vivo challenge assays
Based on pilot studies with outcomes assessed after weekly treatments we selected a 2-wk
treatment period, which is also the turnover period of most DC populations from stem cells
(26). Hence, groups of adult C57BL/6 received 3 i.p. infusions (d0, 7 & 14) of 1.5mg of T15-
IgM or isotype control. To assess the role of PC-binding specificity, some groups received
1.5mg of T15-IgM incubated with 2mg of PC-BSA for 30 min at RT prior to infusion. Other
groups received intravenous 2.5×107 freshly isolated (healthy), apoptotic, or necrotic (by
repeated freeze-thawing) thymocytes in PBS, with bleeds obtained on d16. To induce
apoptosis, congenic murine thymocytes either received 600 Rads using a Cs137 emission source
of radiation, or were treated with 10uM etoposide, then incubated ON in complete media at
37°C with 5% CO2, then washed three times in media before use. Alternatively, mice received
T15-NAb with 2mg of PC-BSA (Biosearch) or BSA as a control. On d17, at 18 hr before
sacrifice mice received saline or challenge with: poly I:C, 100ug; LPS, 30 ug; imiquimod,
100ug or PT CpG ODN1018, 200ug. As pilot studies did not demonstrate in vivo activation
after imiquimod treatment, we instead used 300 ug of SM-360320 (27), due to 100-fold greater
potency. Mice were bled at sacrifice, and suspensions of splenocytes and other lymphoid organs
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evaluated by flow cytometry using standard antibodies and methods (BD-Pharmingen)(17,
20). Antibody immunoassays and inhibitions were performed with PC-BSA, ABA-BSA
(Biosearch) or BSA (Sigma) using IgG (sub)class and T15 clonotype-specific antibodies, as
previously described (20). Soluble factors in DC supernatants and sera were evaluated by
Luminex assay or ELISA (Biosource-Invitrogen).
Inflammatory arthritis models
For CIA studies, 8-wk-old DBA/1 male mice were immunized with avian CII/CFA (Chondrex)
at the tail base on d0 and i.p. boosted on d21 with CII/IFA. Anti-CII antibody levels were
assayed, per manufacturer’s instructions (Chondrex). For histologic analyses, paws and knees
of mice sacrificed on day 44 were decalcified, embedded and sectioned. H&E stained slides
were scored for inflammatory infiltrates and joint erosions, and safranin O stained for cartilage
damage (28). Collagen antibody-induced arthritis was induced in BALB/c mice with 2 mg of
CII-specific monoclonal IgG cocktail injected intravenous on d0, and 72h later each animal
received 50ug of LPS E.coli 011B4 i.p. (Arthogen-CIA kit, Chemicon Int.). Different groups
received T15-IgM or control IgM at 2 mg, or buffer, given as a pre-treatment and every 7d
thereafter. Clinical arthritis was scored visually from 0 to 4 per paw, with a maximum score
of 16 (28).
Statistical analysis
Values are reported as mean+/−SEM unless otherwise stated. Significance was assigned for
P<0.05 by two-tailed t test, with Welsh correction, or ANOVA, as appropriate (Instat,
GraphPad).
Results
NAb enhances local deposition of C1q and MBL on apoptotic cells
To understand the immune modulating properties of T15-NAb, we first characterized its
antibody-effector capabilities, and then assessed how these may affect the innate immune
system. In earlier studies, purified monoclonal T15 clonotypic antibodies were shown to
recognize a subset of dying cells at both early (Annexin V+ 7AAD−) and late (Annexin V+
7AAD+) stages of apoptosis in a PC-inhibitable fashion (17). As a physiologically relevant
source of soluble opsonins, we used sera from B-cell deficient murine MuMT mice that are
therefore deficient in immunoglobulins (Igs)(29). While incubation with Ig-deficient sera
results in low level deposition of C1q on apoptotic cells (30), we found that the addition of
T15-NAb of the IgM isotype increased the amount of C1q recruitment from Ig-deficient sera
onto apoptotic cells (18). Notably, while neither T15-NAb nor C1q interacted with freshly
isolated healthy thymocytes, T15-NAb was responsible for greater than 3-fold relative
increases in C1q deposition on cells at early stages of apoptosis, based on gating on 7AAD−
cells (Figure 1A).
Mannose binding lectin (MBL) is a multimeric collectin immune recognition protein that
initiates the lectin pathway of complement activation, which play roles in immune defenses
but can also interact with certain self-glycoproteins (31). Although not well known for
contributions to antibody-effector functions, because of the reported roles of MBL in apoptotic-
cell recognition (23) and modulation of inflammatory responses (reviewed in (31)), we also
assessed the capacity of T15-NAb to recruit MBL. Indeed, solid phase immunoassays showed
that both T15-NAb as well as the IgM-isotype control had dose-dependent binding to the
labeled recombinant MBL used to detect binding (Figure 1B). However, only T15-NAb
recognized the PC-albumin coated onto the wells and then also interacted with the labeled
MBL reagent. MBL-binding to T15-NAb was inhibited by mannose or N-acetylglucosamine,
but not by N-acetylgalactose, and was also calcium-dependent (Figure 1B), indicating that the
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carbohydrate recognition domain of MBL is responsible for these IgM-interactions presumably
through Fcμ-associated N-glycans (32). In contrast to a single report that binding of a
recombinant IgM-antibody to an experimental antigen disallows constant region interactions
with MBL (32), we found that T15-NAb, but not the isotype control, was capable of concurrent
binding interactions with both PC and MBL (Figure 1B). This indicated that binding
interactions with T15-NAb could potentially amplify recruitment of MBL to immune
complexes.
We therefore examined if T15-NAb could promote binding of human recombinant MBL to
apoptotic thymocytes. As previously reported (23), incubation with MBL alone resulted in
direct deposition of only low levels of this opsonin, predominantly on thymocytes at late stages
of apoptosis and those undergoing secondary necrosis. By contrast, the addition of T15-NAb
significantly enhanced MBL deposition with the greatest increases on thymocytes at early
stages of apoptosis (Figure 1C and Supplemental Figure 1). In further analyses, murine MBL-
specific antibodies (21) were used to directly detect mouse MBL deposited on apoptotic cells
from Ig-deficient sera. Here, these specific detection antibodies showed that T15-IgM similarly
induced the recruitment of both MBL A and C gene products from sera, either separately (not
shown) or together, and the specificity was again confirmed as these interactions were inhibited
by mannose (Figure 1D). Thus, a major function of T15-NAb is the recruitment of both C1q
and MBL to primarily early, but also late, apoptotic cells.
NAb enhances in vivo macrophage clearance of apoptotic cells
To assess whether the T15-NAb can affect the phagocytic clearance of apoptotic cells, we used
a standard sterile peritonitis model (24) with B-cell/Ig-deficient MuMT mice, which received
pretreatment infusions of either T15-IgM, control isotype IgM or saline. Mice were then
injected i.p. with labeled apoptotic thymocytes, and 10 minutes later peritoneal Mφ were
recovered and examined for phagocytized thymocytes (24). We found that in saline or IgM
isotype treated mice, a mean of ~23% of recovered Mφ had engulfed a labeled apoptotic cell
or bleb, while after T15-IgM treatment the proportion of Mφ with ingested apoptotic
thymocytes/fragments increased to ~36%. Hence, T15-IgM treatment resulted in a 50–60%
increase in the level of apoptotic phagocytosis, compared to the isotype control (P<0.0004) or
saline treatments (P<0.0001, Figure 1E). By contrast, we found that in T15-IgM treated mice,
after injection of labeled healthy thymocytes <3% of recovered peritoneal Mφ had engulfed a
labeled thymocyte (not shown). Notably, increases in the efficiency of apoptotic clearance in
the same assay, akin to those mediated by T15-NAb, have also been documented when wild-
type mice were compared with either C1q- or MBL-deficient mice (24,33). Indeed, we found
that T15-NAb coated apoptotic thymocytes formed chains and clusters, which were engulfed
by peritoneal Mφ (Figure 1F). Flow cytometric analysis of the recovered peritoneal cells
demonstrated that T15-NAb enhanced the elimination of both early and late stage apoptotic
cells (P<0.004, Supplemental Figure 1). Thus, T15-NAb significantly enhances the in vivo
phagocytosis of apoptotic cells by peritoneal macrophages, with an influence akin to the
individual contributions of MBL and C1q for phagocytic clearance.
NAb suppresses LPS-induced IL-6 secretion by RAW264.7 macrophage-like cell line
As interactions with apoptotic cells are reported to blunt inflammatory responses (34), and we
found that T15-NAb enhances interactions of phagocytes with apoptotic cells, we also assessed
whether this NAb can affect pro-inflammatory responses of the RAW264.7 macrophage-like
cell line. In a representative study, T15 IgM displayed a significant dose-dependent inhibition
of induced TNF-α secretion (P<0.0001), with 55% inhibition by 1 ug/ml, 74% at 4 ug/ml and
83% inhibition at 20ug/ml, while the IgM isotype control had no effect (Figure 2A). T15-NAb
similarly inhibited TLR-induced IL-6 secretion (Figure 2B). However, TLR-mediated
stimulation also caused a significant level of cell death (data not shown), so we could not control
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for a requirement for apoptotic cells for T15-mediated inhibition. Nonetheless, these findings
document that the T15 NAb can induce a dose-dependent inhibition of TLR4-induced
macrophage secretion of the key pro-inflammatory factors, TNF-α and IL-6.
NAb associates with MBL and C1q to enhance DC phagocytosis of apoptotic cells
At early stages of differentiation, immature DC share many cell surface receptors as well as
the phagocytic capacities of Mφ (35). We therefore used a standard culture system to generate
CD11c+ immature DC (25), and studied the phagocytic capacity of bone marrow-derived
conventional DCs (18,36–38). After incubation with labeled thymocytes, the purified CD11c
+ immature DCs were discriminated in flow cytometry studies based on size (i.e., FSC), and/
or staining for CD11c (Figure 3), and the proportion of immature DC sub-population that
ingested CFSE-tagged apoptotic cells was quantified based on the associated shift in
fluorescence (Figure 3A), using methods previously confirmed with side-by-side microscopic
quantitation (18). Importantly, under serum-free conditions (i.e., devoid of Ig and opsonins),
we have recently shown that DC displayed the same low frequency of phagocytosis of apoptotic
thymocytes as with labeled healthy thymocytes ((18) and data not shown), which is consistent
with the notion that efficient phagocytosis of apoptotic cells, compared to viable cells, is
dependent on the availability of specific serum factors.
As levels of the opsonins, C1q and MBL, are reported to directly correlate with the efficiency
of apoptotic cell elimination (39), we also used this system to look for potential interactions
of T15-NAb NAb in serum-free media with the addition of these opsonins. Here, we found
that addition of recombinant MBL provided a significant dose-dependent increase in DC
phagocytosis, with dramatic increases seen only when T15-NAb was present (Figure 3).
Strikingly, in similar serum-free cultures with a fixed amount of T15-NAb, MBL conveyed
much greater dose-dependent increases in the efficiency of phagocytosis than we have found
was associated with supplementation with purified C1q (Figure 3C&D)(18). Furthermore, in
cultures with T15-NAb and the highest level of MBL, the further addition of C1q resulted in
only a minor additional increases in DC phagocytosis. In fact, the level of phagocytosis seen
in cultures with MBL at 20 μg/ml were comparable to those instead supplemented with Ig-
deficient sera (Figure 3C&D). Hence this NAb-dependent influence on innate immune function
was limited by the availability of MBL and C1q, which were redundant in their capacity to
enhance the influence of T15-NAb on DC phagocytosis. Unexpectedly, in this assay MBL
appeared to be more potent than C1q, as MBL alone conveyed nearly the full level of
phagocytosis associated with Ig-deficient sera. We also compared levels of phagocytosis with
T15-IgM (at 20 ug/ml) without the addition of sera, or with supplementation with 10% Ig-
deficient sera, or after heat inactivation, which was thereby shown to reduce by 83% the
contribution of serum factors to T15-mediated enhancement of iDC phagocytosis of apoptotic
cells (not shown).
To confirm the requirement of the antigen-binding specificity of the NAb, we performed studies
with saturating amounts of MBL and a limiting concentration of T15 IgM. Here we found that
with T15-NAb and MBL, the frequency of DC that engulfed apoptotic cells was still nearly
twice as high as with serum-free conditions alone (Figure 3C&D). Importantly, preincubation
with PC-BSA significantly reduced (>50%) the T15-IgM mediated increase in the phagocytic
engulfment of apoptotic cells (P<0.004), while incubation with an irrelevant control BSA-
conjugate instead increased phagocytosis by ~25% (p=0.0021)(Figure 3A). Hence, the capacity
of T15-NAb to enhance apoptotic cell engulfment was also shown to be dependent on its PC-
binding specificity.
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NAb in association with MBL and C1q inhibits TLR-induced DC maturation
To assess the effects of NAb-apoptotic cell complexes on DC maturation, we studied how
different culture conditions can affect co-expression of the membrane-associated co-
stimulatory molecule, CD80, and intracellular IL-12 p40 expression, which can be upregulated
following TLR stimulation. Notably, control studies demonstrated that even without TLR
agonists, these primary CD11c+ DC display a range in their phenotype (Figure 4A), which in
part reflects the persistent influence of GM-CSF and IL-4 (40) At first, we confirmed that either
LPS or poly I:C induced the maturation of DC, based on evidence of decreased representation
of less mature (i.e., CD80low IL-12p40−) DC, compared to culture without these stimuli
(P<0.0001)(Figure 4A).
We next evaluated whether the addition of a large number of apoptotic cells alone can affect
DC maturation. Notably, we uniformly found that in DC cultures stimulated with LPS or poly
I:C, the addition of equal numbers of apoptotic thymocytes significantly inhibited the TLR-
induced DC maturation. This result was a consistent finding whether or not antibody and
opsonin was added, and these differences were highly significant when we compared paired
cultures without or with added apoptotic cells (P<0.0001, paired t test, N=3 replicate cultures)
(data not shown). Hence, as previously reported, apoptotic cells themselves, when present in
substantial numbers, inhibit TLR-induced conventional DC maturation (41). Importantly, we
found that after DC alone were in culture for 24 hr, 10–15% of recovered cells were Annexin
V+ apoptotic cells and fragments (unpublished data)(Figure 4A). Predictably, when added to
these DC cultures, T15-NAb coated these apoptotic DC (and their breakdown products) but
not viable DC (Supplemental Figure 2). These T15-NAb-coated apoptotic DC were
phagocytosed by viable immature DC (Supplemental Figure 2), while T15-NAb otherwise had
no adverse effects on viability or proliferation. Thus, inherent to the biology of these primary
cells, DC cultures contained apoptotic cells and debris that form into complexes with T15-
NAb.
We therefore tested the hypothesis that T15-NAb can suppress TLR-induced DC maturation,
in the presence of suitable opsonins, and only the limited number of the dead cells/fragments
that are continuously generated in culture. We uniformly found that addition of T15-NAb
increased the proportion of less mature DC, compared to cultures with isotype control or
without IgM (Figure 4A–C). This was also found in T15-NAb containing cultures without
supplemented opsonic factors, may reflect the potential carryover of serum factors on the
apoptotic thymocytes, or the production by immature DC of small amounts of C1q and MBL
(42,43) and possibly other factors. Nonetheless, T15-NAb significantly suppressed DC
maturation in cultures stimulated with either poly I:C or LPS (P<0.05). There was also a trend
toward less mature DC in cultures with T15-NAb but without TLR agonist (Figure 4B&C),
presumably due to blunting of the residual influences of GM-CSF and IL-4.
There was a consistent hierarchy in the effects of C1q and MBL on T15-NAb suppression in
these replicate LPS or poly I:C stimulated serum-free cultures. The least inhibition of DC
maturation was found in the absence of additional supplements, with greater inhibition with
the addition of C1q, and even greater suppression with MBL. The greatest inhibition was seen
when T15-NAb was added to TLR-stimulated cultures that had been supplemented with both
C1q and MBL, as this resulted in significantly more immature DC than other T15-NAb
containing cultures, whether or not MBL or C1q were added (P<0.015). Indeed, T15-NAb, in
the presence of both C1q and MBL, effectively blocked DC maturation induced by LPS (Figure
4B) or poly I:C (Figure 4C) to the level found in cultures without TLR agonist and T15-NAb.
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NAb inhibits in vitro inflammatory responses of DC
We next assessed whether T15-NAb, which binds apoptotic material in culture and enhances
phagocytosis, can modulate other features of in vitro responses of DC in sera-containing media
with a broad range of agonistic TLR ligands, including poly I:C, LPS, imiquimod, and CpG
DNA. Indeed, inhibition was again documented for surface maturation/activation markers,
MHC II, CD40, CD86, and CD80 (Figure 5A and unpublished data) and for secretion of pro-
inflammatory cytokines (TNFα, IL-6, IL-12p70), CC chemokines (KC, MCP-1, MIP-1α), and
CXC chemokine (IP-10) (Figure 5B and unpublished data). By real-time PCR analysis, T15-
NAb also inhibited LPS induction of TNF-α, IL-1β, IL-6, and IL-12 transcripts (Figure 5C and
unpublished data). By contrast, at even high concentrations, the B-1 cell derived IgM isotype
control, which showed only minor binding to late-stage apoptotic cells, resulted in little or no
inhibition. Further studies showed that T15-NAb-mediated inhibition of IL-6 production was
>80% reduced by a T15-specific anti-idiotypic antibody that blocks the T15 PC-binding site
(19). Hence, our findings support the hypothesis that the specific interactions of T15-NAb with
dead and dying cells can inhibit DC maturation and suppress activation-associated expression
of cytokine and chemokine factors.
To assess for potential pathways responsible for these T15-NAb-mediated inhibitory activities,
we first examined expression of IL-10 and TGF-β1, which are both implicated in the inhibitory
properties of regulatory DC responses. Neither, however, were induced, at either the transcript
or protein level by T15 exposure and, in fact, T15-NAb inhibited the LPS-mediated induction
of IL-10 (Figure 5C and unpublished data). The suppressive effects of T15-NAb were also
unimpaired by IL-10 neutralizing antibodies or in DC from IL-10-deficient mice (unpublished
data).
T15-NAb inhibits in vivo inflammatory responses
To determine whether T15-NAb can also inhibit in vivo inflammatory responses, we
investigated the effects of infusions of purified T15-IgM on in vivo innate immune pro-
inflammatory responses. Indeed, after two weeks of T15-NAb exposure, which corresponds
to the approximate turnover period for DC populations (26), the T15-NAb group had 17–21%
less splenic CD11chi DCs (P<0.02, N=7–8 per group) and significantly lower levels of surface-
expressed MHC class II (P<0.02), which is consistent with evidence that T15-NAb can inhibit
in vitro DC maturation. Importantly, responses to the TLR agonists, poly I:C (TLR3), LPS
(TLR4) and CpG nucleotides (TLR9), were also inhibited by T15-NAb pretreatment, with
impaired induction of activation and maturation markers, CD86 and MHC II, on splenic Mφ
and CD11chi DC (Figure 6A&B). Furthermore, T15-NAb also significantly inhibited responses
to the potent TLR7 agonist, SM-360320 (27)(Figure 6A), as well as poly I:C induction of other
co-stimulatory molecules such as CD40, CD80 and B7-DC (unpublished data). T15-NAb
treatment also blunted poly I:C-induced blood levels of pro-inflammatory cytokines (IL-6,
IL-12, IL-17, TNFα) and chemokines (MIP1α, MCP-1, KC and IP-10)(Figure 6C). In addition,
NAb treatment significantly reduced the production of IL-6 and IL-12 by peritoneal Mφ
(unpublished data). Confirming the role of the PC-binding specificity, preincubation with an
excess of PC-conjugate before T15-NAb infusion antagonized >78% of the in vivo inhibitory
effects. Hence, elevated levels of T15-NAb drastically reduced the in vivo responsiveness of
the innate immune system to a range of pro-inflammatory stimuli.
Apoptotic cells induce anti-inflammatory NAbs with the properties of T15
We reasoned that apoptotic cells might be the main antigenic target for in vivo T15-related
NAb responses. To examine the in vivo relationship between T15-NAb, apoptotic cells, and
inflammation, we infused large numbers (25×106) of apoptotic thymocytes into naïve mice
that had low but detectable natural T15 levels (Supplemental Figure 3, with data deposited in
the GEO repository under accession number GSE14969
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http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE14969). Notably, this treatment also
blunted Mφ and DC activation responses (Figure 6B&C). Moreover, co-treatments of apoptotic
cells plus T15-NAb trended toward greater suppression of in vivo poly I:C-induced activation
responses, compared to either apoptotic cells alone, or apoptotic cells plus isotype control
(Figure 6B&C). Inhibition was also observed for peripheral blood pro-inflammatory cytokines
and chemokines (Figure 6C). Hence, in vivo apoptotic-cell treatment unexpectedly produced
a similar inhibitory effect as demonstrated for T15-NAb.
While apoptotic cells were anti-inflammatory, primary necrotic thymocytes, which can
exacerbate autoimmune disease (44), were not. In fact, infusion of necrotic cells alone
significantly increased the expression of activation markers after poly I:C challenge (Figure
6B&C). Strikingly, T15-NAb, albeit to a lesser extent, still blunted the proinflammatory effect
of necrotic-cell treatment (Figure 6B&C), suggesting that the raised T15-NAb levels resulted
in formation of inhibitory complexes with host apoptotic cells.
Extending recent observations (18), we also tested whether infusions of apoptotic cells in these
studies induced relevant T15-like antibody responses similar to pneumococcal immunization
(12). Indeed, 10 days after a single infusion of such cells without adjuvant, 8-fold increases in
circulating IgM anti-PC levels were detected. Although responses varied in individual mice,
three weekly apoptotic-cell infusions generally raised circulating levels of T15-clonospecific
(19) and IgM anti-PC antibodies more than 40-fold higher than in naïve mice (p<0.01)
(Supplemental Figure 3A&B) (18). In contrast, infusions of healthy or necrotic-cells yielded
only minor changes, which is consistent with findings that apoptotic-cells induced ~20-fold
increased numbers of PC-specific splenic IgM-secreting cells (18). In fact, apoptotic-cell
infusions induced IgM antibodies to PC-containing determinants to levels equivalent or higher
than those that followed T15-NAb infusions (Supplemental Figure 3C), which required
substantial doses due to the short half-life of IgM (45). Apoptotic cells also induced IgG anti-
PC responses, but these levels were much lower (5.5±2.5 ug/ml) and overwhelmingly of the
IgG3 subclass, indicating a mainly T-cell independent response (Supplemental Figure 3D, and
unpublished data). Hence, despite evidence that apoptotic cells may suppress some innate
immune functions, intravenous treatment nonetheless induced robust B-cell responses, even
without the use of adjuvant.
To assess the relevance of these active immune responses to the above described T15-NAb
studies, we have recently shown that incubation of sera from apoptotic cell treated mice resulted
in IgM binding to apoptotic cells, and enhanced antibody-dependent C1q recruitment to
apoptotic cells, both of which were inhibited by PC preincubation (18). We now used the solid
phase MBL-recruitment anti-PC immunoassay, and found that apoptotic cell treatments
induced high levels of MBL-binding anti-PC antibodies (384±89ug/ml, N=4), while negligible
levels were found before treatment (< 2 ug/ml, P<0.0001). Akin to the properties of the
monoclonal T15-NAb, MBL recruitment by post-immune anti-PC responses was also >90%
inhibited by preincubation with mannose or N-acetyl glucosamine, or with EDTA in the media
that demonstrated calcium dependence, while MBL binding was not inhibited by N-acetyl
galactose (not shown). Compared to naïve sera, incubation in apoptotic-cell post-immune sera
greatly increased levels of IgM binding to apoptotic cells, with similar increases in the
recruitment of C1q and MBL. Notably, the greatest IgM-associated enhancement was seen on
early apoptotic cells (i.e., 7AAD−)(18)(Figure 6D). Preincubation of T15-NAb with PC-BSA
also greatly reduced the deposition of IgM and also MBL (Figure 6D) and C1q (18) on apoptotic
cells. Furthermore, similar to purified T15-NAb (Figure 3A), sera obtained after apoptotic-cell
treatment, which had markedly increased levels of IgM-antibodies to apoptotic cells, also
suppressed in vitro TLR-mediated activation of cultured DC (unpublished data).
Chen et al. Page 10
J Immunol. Author manuscript; available in PMC 2010 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Suppression of inflammation by apoptotic cells requires B cells or T15-NAb
B-cell-deficient MuMT mice were next used to assess the requirement for IgM in the in vivo
inhibitory properties of apoptotic-cells. Strikingly, infusions of apoptotic cells alone had little
or no effect on poly I:C-induced cellular activation or cytokine/chemokine responses in B-cell
deficient mice (Figure 7 and unpublished data). In contrast, T15-NAb, but not isotype control,
treatment of B-cell deficient mice induced the same blunting of TLR-induced cell activation
and cytokine/chemokine production as demonstrated in C57BL/6 mice. Overall, these findings
indicate that the suppressive effect of apoptotic cell infusions in vivo is dependent on the
induction of antibodies with certain specificities, which include anti-PC reactivity.
NAb protects from inflammatory arthritis
As inflammatory pathways involving Mφ, DC and TLR have been implicated in the
pathogenesis of autoimmune arthritis (46), we studied collagen-induced arthritis (CIA) in
DBA/1 mice (47) to test the hypothesis that high levels of T15-NAb might suppress the
development of inflammatory disease (Figure 8 & Supplemental Figure 4). Significantly,
pretreatment with the anti-PC NAb markedly reduced clinical disease activity, synovial
leukocytic infiltrates, and bone and joint damage (Figure 8A–C). Notably, there were no
differences in total IgG-, or IgG1- and IgG2a- subclass anti-CII levels induced by collagen
immunization in the different treatment groups (unpublished data) suggesting that T15-NAb
was primarily inhibiting the end organ inflammatory response. In other studies, infusions of
apoptotic cells into DBA/1 mice yielded increased IgM anti-PC levels and protection from
clinical arthritis, while infusions of primary necrotic cells did not (Figure 8A).
To further define the adaptive immune systems role in this process, we studied the effects of
T15-NAb on passive transfer arthritis induced by anti-CII IgG, in which lymphocytes do not
a play central role (48). Here, we again found that T15-NAb treatment significantly diminished
joint swelling (Figure 8D). Together, these findings indicate that the regulatory properties of
T15-NAb in these models of arthritis act through the blunting of pro-inflammatory effector
mechanisms mediated by the recruitment of IgG-autoantibody immune complexes.
Discussion
In health, inflammatory responses are critical for combating infection and tissue injury, but of
equal importance are control mechanisms that remove dying cells and prevent over-exuberant
responses detrimental to the host. Here, we document several previously unrecognized and
functionally important features of the prototypic anti-PC NAb, T15. First, by virtue of its
capacities for PC-specific binding to apoptotic cells, in addition to C1q (18), T15-NAb also
facilitates the deposition of MBL onto apoptotic cells, particularly early apoptotic cells that
are generally less susceptible to direct opsonin recruitment. Second, T15-NAb, by recruiting
the deposition of both C1q and MBL, enhances the phagocytosis of early and late apoptotic
cells. Third, T15-NAb, by forming complexes with MBL and C1q on apoptotic cells, can
effectively suppress TLR-induced maturation of conventional DCs. Fourth, T15-NAb inhibits
Mφ and DC secretion of pro-inflammatory cytokines and chemokines in response to agonists
for a broad range of TLR, and it is also capable of inhibition of in vivo phagocyte activation
and suppression of potentially harmful inflammatory responses. Fifth, infusion of high doses
of T15-NAb, or large numbers of apoptotic cells that induce IgM anti-PC Abs, can inhibit the
development of autoimmune inflammatory arthritis. Taken together, these findings identify a
hitherto unsuspected set of regulatory functions of this type of NAb.
Our findings therefore characterize the potential functional roles of T15-NAb, which is
representative of a dominant antibody response induced by apoptotic cells. Multiplex
autoantigen-microarray assays have shown that apoptotic-cell treatment of C57BL/6 mice
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induces a dominant IgM response directed toward PC-containing antigens; including PC-
albumin, pneumococcal vaccine and capsular polysaccharide alone, or the self-antigen,
oxidized LDL, with little or no reactivity to a large panel of other autoantigens (18)
(Supplemental Figure 3)(17). In C57BL/6 mice, T15-related antibodies represent about half of
all induced antibodies that recognize apoptotic cells (18). In fact, apoptotic cells induced
relatively low levels of anti-DNA IgM (18)(Supplemental Figure 3), which contrasted with an
earlier report (49). Taken together, apoptotic cells do not appear to induce non-specific
polyclonal IgM responses, but instead provoke an antibody response with a strong bias toward
immune recognition of PC-neo-determinants.
In contrast to the classical theory that a healthy immune system requires an absolute avoidance
of self-reactive lymphocyte clones (i.e., “horror autotoxicus”)(50), the repertoires of innate-
like B cells are known to incorporate some level of autoreactivity (3,51), and self-ligands are
believed essential for their positive clonal selection and survival (52). Based on evidence that
T15 B cells recognize an immunodominant self-antigen in apoptotic cells/debris, it is plausible
that the apoptotic-cell turnover occurring during ontogenesis provides the self-ligands for the
early selection of these B-1 cell clones. Moreover, as anti-apoptotic cell antibodies are part of
the physiologic repertoire, our findings may explain why mice without circulating IgM
spontaneously develop IgG-autoantibodies and lupus-like disease (53), as this may result in
impaired clearance of apoptotic breakdown products, as well as the loss of an NAb regulatory
influence that otherwise can suppress overexuberant responses of innate phagocytes (54).
Although the potential immunosuppressive roles of NAbs have been generally overlooked,
there is nonetheless overwhelming evidence that C1q and MBL have immune modulating
properties (31). Based on evidence that humans with a homozygotic deficiency in C1q have a
high penetrance of lupus-like systemic autoimmunity (55), studies of murine models confirmed
this also occurs on certain genetic backgrounds, and is associated with an accumulation of
apoptotic bodies in the kidney and glomerulonephritis in 25% of animals (56). These data are
consistent with the hypothesis that C1q deficiency, resulting in inefficient clearance of
apoptotic cells, leads to the release of intracellular components, exposure of the immune system
to self-Ags, and subsequent autoimmunity. Like C1q deficiency, MBL deficient mice also
display defects in apoptotic clearance and are prone to inflammatory conditions (33), although
it is controversial whether MBL deficiency also influences autoimmune predisposition or
disease severity (57).
While MBL is well known for its contributions to the clearance of microbial pathogens and
apoptotic cells, its potential role in IgM-antibody effector functions has been little explored.
While these opsonins can be directly deposited at low levels onto apoptotic cells, this is
primarily on late stage apoptotic and secondary necrotic cells (23). Our data show that MBL
(and C1q) are recruited by T15-NAb to early stage apoptotic cells, and this is associated with
both enhanced phagocytosis and reduced inflammation. Significantly in vivo apoptotic-cell
immunization was shown to induce IgM-anti-PC responses that also recruited MBL- and C1q-
binding, confirming the physiologic relevance of their essential yet redundant roles in NAb-
effector functions. The effector function for MBL recruitment has also been associated with
B-1 cell derived IgM antibodies with a different self-specificity (58).
Apoptotic-cell phagocytosis by immature DC enables constant sampling and presentation of
self-antigens in a manner believed essential for the maintenance of tolerance (59). Yet, if
apoptotic cells are not quickly cleared, cellular progression to necrosis can lead to the release
of pro-inflammatory substances and autoantigens that can lead to breaches in self-tolerance
(60). Hence the efficient elimination of the immense number of cell corpses generated each
day is therefore indispensable for tissue homeostasis, resolution of inflammation, and
prevention of autoimmune disease. We provide direct evidence that a monoclonal B-1 cell
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NAb can directly induce deposition of MBL and C1q, which can each directly enhance cell-
corpse clearance, as well as inhibit immature DC activation and differentiation. The anti-
inflammatory influences of T15-NAb are no doubt aided by the capacity to flag cells and
fragments at earlier stages of apoptosis for clearance.
The association of MBL with an apoptotic cell alone has been reported to be inadequate for
activation of the complement cascade (23), and host cells themselves express specific
complement inhibitors that also provide protection from inappropriate complement activation
(61). However, other recent reports have shown that polyclonal serum IgM can induce the
deposition of C3 products, which enable recognition by Mac-1/CR3 on Mφ also implicated in
the clearance of apoptotic cells (62,63). We therefore repeated our in vitro challenge studies
with TLR agonists in serum-free cultures of C3-deficient DC, but found no reduced capacity
of T15-NAb to enhance phagocytic clearance and inhibit inflammatory responses (18)(data
not shown). Our pilot studies also indicate that the in vivo anti-inflammatory activities of T15-
NAb are unimpaired in C3-deficient mice (unpublished data). Taken together, we believe these
findings rigorously rule out an absolute requirement for downstream propagation of
complement pathway activation in the immune modulatory properties of T15-NAb.
Our studies highlight the otherwise overlooked capacity for antigen-specific IgM antibodies
to affect the fundamental process of apoptotic clearance and regulation of TLR responses. As
discussed above, we postulate that T15-NAb, which recognizes apoptosis-specific
determinants, by increasing the amount of C1q and MBL bound on apoptotic cells facilitates
their phagocytosis and also enhances apoptotic cell-mediated inhibition of macrophage and
DC activation. This process potentially involves receptors, such as CD36, CD93 αvβ3,
calreticulin, and the low density lipoprotein receptor (LRP-1, CD91) that have been implicated
in MBL- and C1q-enhanced apoptotic clearance (39,64,65). However the topic remains
controversial, especially in light of the recent report, which also used etopside-induced
apoptotic thymocytes, to demonstrate that LRP-1 was not essential for the enhancement of
phagocytosis by murine macrophage (38). In addition, T15-NAb also appears to enhance
immunomodulatory cellular interactions of complexed apoptotic cells and fragments, for which
there are also a number of candidate receptors and at times conflicting literature (reviewed in
(66)). Yet, even though T15-NAb enhanced the phagocytosis of cell corpses and also blunted
TLR-induced DC maturation, the underlying pathways are not necessarily entirely identical,
as these effects can be mediated by distinct residues in the intracellular domain of an apoptotic
cell receptor (67). Our preliminary studies indicate that the suppressive effects of T15-NAb on
DC involve inhibition of inflammatory signaling pathways (unpublished observations).
However, although previous studies implicated IL-10 and TGF-β1 in the anti-inflammatory
effects of apoptotic cells (reviewed in (66)), we were unable to find evidence to support this
for T15-NAb, but this may in part reflect that such responses may primarily occur at later time
points. Albeit, it remains possible that IL-10 and TGF-β might contribute to the in vivo effects
of T15-NAb.
We first appreciated the pro-homeostatic properties of T15-NAb in the setting of the chronic
inflammatory disease, atherosclerosis. Indeed, earlier in vitro studies initially suggested that
T15-IgM might act by blocking apoptotic-cell binding to elicited Mφ (15). By contrast, we
now document that these NAb-mediated properties are linked to the contributions of the
opsonins, MBL and C1q, that were likely absent or in low amounts in the earlier study (15).
Indeed, our current studies, which used more physiologically relevant assays, instead clearly
showed that T15-NAb enhanced in vivo phagocytic clearance by Mφ and directly inhibited
inflammatory responses. These mechanisms now appear to be a more likely explanation for
previous evidence that immunization with a PC-vaccine suppressed atherosclerosis (12).
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The current studies of autoimmune arthritis models also showed that treatment with T15-NAb
significantly reduced inflammatory joint injury despite grossly unimpaired collagen-specific
lymphocyte responses. Our studies were limited to prevention of the initiation phase of disease.
However we believe these findings may still be clinically relevant, despite the fact that C1q
and MBL deficiency do not specifically predispose to inflammatory arthritis, and such
conditions are not known to result from defects in apoptotic clearance. Yet in vitro and in vivo
studies in C57BL/6 did demonstrate a potent capacity to inhibit phagocyte production of TNF-
α, IL-6, IL-17, IL-12 and key chemokines that recruit other cell types into inflammatory
responses. Hence, we postulate that raising levels of such NAbs may provide benefits in
conditions as diverse as rheumatoid arthritis, and perhaps also atherosclerosis (12), that are
associated with innate immune cell recruitment and uncontrolled activation at sites of
pathologic inflammation. Overall, these findings suggest that administration of T15-NAb, or
induction of T15-NAb by apoptotic cells or microbial products, might be of general utility for
the suppression of deleterious inflammatory conditions.
Earlier studies of T15 antibodies suggested that the driving force for the recurrent expression
of these germline-encoded NAbs was linked to protection against microbial pathogens that
bear PC molecular patterns, which is reminiscent of functions of receptors of innate immune
cells. Our studies may now provide clues to unsuspected primary functional roles of the earliest
B lymphocytes, the strong evolutionary pressure to maintain the anti-PC specificity, and why
we are born with antibodies in our bloodstreams. Indeed, NAbs with the binding properties of
murine T15, to PC and other phospholipid-derived determinants, are also highly conserved in
humans from birth (5,68), with documented increases in healthy twins genetically predisposed
but unaffected by SLE (22). Such antibodies may also be highly represented in the repertoire
of malignant CD5+ chronic lymphocytic leukemia that are human B-1 cell equivalents (69).
While there are many other known innate pathways for limiting inflammatory responses, we
postulate that some T-cell independent immunoregulatory NAb circuit arose as a means to
enhance the clearance of apoptotic cells, and to suppress the induction and hasten the resolution
of inflammatory responses. These same primitive pathways may provide a novel therapeutic
strategy for the treatment of chronic inflammatory diseases.
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Collagen type II
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Malondialdehyde
MBL  
Mannose Binding Lectin
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PC  
Phosphoryl choline
poly I  
C, polyinosinic:polycytidylic acid
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Figure 1. T15-IgM NAb enhances deposition of C1q and MBL on apoptotic cells and increases their
in vivo phagocytic clearance by peritoneal Mφ
(A) To assess for C1q deposition, etoposide-treated apoptotic thymocytes were incubated in
50% muMT sera in saline or with monoclonal IgM (20 ug/ml), then washed and stained with
7AAD (to assess membrane integrity) and anti-murine C1q or isotype control, as indicated.
While labeled Annexin V was used to document apoptosis, it was otherwise omitted to avoid
interference with C1q-binding. By gating on early apoptotic cells (i.e., 7AAD−), which are
indicated by the arrows, addition of T15 IgM was shown to increase more than 3-fold the level
of C1q deposition from Ig-deficient sera, compared to saline or IgM isotype control. At bottom,
control studies demonstrated no significant signal (left) on early apoptotic cells with the isotype
control detection reagent, (middle) or with early apoptotic cells without MuMT sera but with
T15 IgM (no sera), or (right) for C1q deposition onto freshly isolated live cells in the presence
of T15-NAb. (B) ELISA studies show binding of IgM with a biotinylated detection reagent to
different precoated antigens, which are listed at bottom. With a precoat of PC-albumin, T15-
IgM (at 2 ug/ml) displays specific MBL- and antigenic-binding, but not to albumin alone.
Specific MBL binding is blocked by mannose or N-acetylglucosamine (NAcGlu) but not by
N-acetyl galactosamine (NAcGal) at 20 mM. Binding also requires CaCl2, and is absent in
10mM EDTA-containing buffer. (C) Etoposide-treated or γ-irradiated apoptotic thymocytes
were incubated with human recombinant MBL in the absence or the presence of purified
monoclonal IgM, then stained with labeled anti-human MBL. At top, binding is shown after
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gating on early (7AAD-Annexin V+) apoptotic cells. At bottom left, control studies
demonstrated no significant signal on apoptotic cells with the biotinylated isotype-control
detection reagent. (D) To assess for the capacity to recruit murine MBL from sera, etoposide-
treated thymocytes were incubated with MuMT sera in the presence of saline or purified
monoclonal IgM, as indicated. Cells were stained for IgM, and with labeled anti-mouse MBL
A and MBL C. In control studies (bottom), only background reactivity is seen after incubation
of apoptotic cells sera and T15-IgM, with staining with an isotype control reagent (left).
Incubation without sera yielded background signal with anti-MBL A+C detection, while MBL
deposition was greatly reduced by the addition of mannose (50 uM) to sera and T15-IgM. T15-
IgM and sera incubation did not result in MBL deposition on healthy cells (right). (E) In vivo
Mφ mediated apoptotic clearance was evaluated, in three independent experiments, as
indicated (solid triangle, open circles and solid circles), with 2–4 B-cell deficient mice in each
group. Mice received either T15-IgM, isotype control IgM or saline treatment before
instillation of apoptotic thymocytes (total N=9–10/group). Values for each mouse represent
the phagocytic index after 10 min, (i.e., proportion of recovered peritoneal Mφ that had
engulfed labeled apoptotic thymocytes) (F) Cytospin preps show NAb enhanced phagocytic
engulfment of apoptotic cells by peritoneal Mφ from B-cell deficient mice that received IgM
or saline. After 16 hr, thymocytes labeled with SNARF-1 fluorochrome (red) were instilled
i.p., with sacrifice 10 min later. Mφ were detected by F4/80 FITC (green). At top, treatment
with specific IgM treatment is indicated, with either apoptotic or healthy freshly isolated
thymocytes, as indicated below. Results are representative of three or more independent
experiments.
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Figure 2. T15-NAb inhibits LPS induced secretion of TNF-a and IL-6 by the RAW264.7
macrophage cell line
RAW 264.7 murine macrophage cells were stimulated overnight without or with LPS (100 ng/
ml), and supernatants were assayed for (A) TNF-α and (B) IL-6. Values represent mean +/−
SEM or 3 or more replicate cultures. Representative of 4 experiments.
Chen et al. Page 21
J Immunol. Author manuscript; available in PMC 2010 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 3. T15-NAb enhances in vitro phagocytosis of apoptotic thymocytes by conventional DC
Bone marrow derived purified DC were cultured with equal numbers of CFSE-labeled
apoptotic cells in serum-free media for 1 hr. Cultures were supplemented with IgM, purified
human C1q, recombinant human MBL, or Ig-deficient murine sera as indicated. For analysis,
cell fragments were removed based on forward scatter, which enabled the discrimination of
the proportion of DCs that have engulfed apoptotic cells (ACs). (A) Cultures included limiting
concentrations of T15 or isotype control IgM (5 ug/ml), with saturating amounts of MBL (40
ug/ml), as indicated. High levels of AC phagocytosis requires co-culture with both T15-NAb
and MBL, while the level of phagocytosis is inhibited by preincubation with PC-BSA (50ug/
ml) but not by control protein conjugate (ABA-BSA). (B) PC significantly inhibited T15-NAb
mediated enhancement of AC phagocytosis, as shown in data compiled from replicate cultures.
(C) MBL is responsible for large dose-dependent increases in AC engulfment increases in the
presence of T15-IgM (at 20 ug/ml), with significantly less effects in cultures without IgM or
with isotype control (20 ug/ml). (D) Replicate cultures demonstrate equivalent significant T15-
IgM mediated increases with addition of Ig-deficient sera, while C1q also conveys significant
but smaller increases in T15-NAb dependent AC phagocytosis, as recently reported (18).
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Figure 4. T15-NAb inhibits in vitro TLR induced maturation of conventional DC
Bone marrow mononuclear cells were cultured with GM-CSF and IL-4 for 5 days, then purified
with anti-CD11c beads prior to overnight culture in serum-free media. (A) LPS induces
maturation of DC, based on increased CD80 and IL-12p40 expression, which is inhibited by
T15 IgM (20 μg/ml) in cultures supplemented MBL (20 μg/ml) and C1q (80 μg/ml). DC are
shown to be heterogeneous in their level of maturation, even in the absence of LPS or poly I:C.
Based on scattergram analysis, these overnight cultures contained 10–18% dead cells and
fragments. (B) T15-NAb, in the presence of MBL and C1q, inhibits LPS induced DC
maturation. Values for CD80− IL-12p40low DC, as gated in panel A, is shown from four or
more replicate cultures (mean+/− SEM). (C) T15-NAb, in the presence of MBL and C1q,
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inhibits poly I:C induced DC maturation. Data from four or more replicate cultures are shown.
Open bars are without IgM, dark bars are with Isotype control, and vertical strips are with T15
IgM at 20 ug/ml. Significance as indicated: * P<0.05; ** ≤ 0.01; *** ≤0.0001; **** ≤0.0003.
Representative of three independent experiments.
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Figure 5. T15-NAb treatment blunts in vitro DC responses to TLR agonists
(A) CD11c+ selected myeloid DC were cultured in replicate with agonists for TLR3 (poly I:C),
TLR4 (LPS), TLR7 (imiquimod), or TLR9 (PT CpG ODN1018), without or with T15-IgM or
isotype control at indicated concentrations. (A) Histograms of MHC II and CD40 on DC after
culture without or with stimulant (indicated above panel) are depicted. Mean fluorescence
intensity is listed without and with IgM, at indicated concentrations. (B) Supernatants from
these overnight cultures of conventional bone-marrow derived DC were assessed for levels of
pro-inflammatory cytokines and chemokines, which were determined from standard curves
(mean+/−SEM). Results are shown without (none) or with stimulants (poly I:C, pIC;
imiquimod, imiq) without or with T15-IgM, isotype IgM control, at 10 ug/ml. The isotype
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control was associated with minor inhibition of MCP-1. (C) Transcript levels were determined
by real time PCR for murine BM-derived CD11c+ DC, under indicated cultured conditions
over time (min). DC were preincubated with T15-NAb or isotype control before time “0”
sampling, then LPS was added. Amplification for TGFβ is β1 isoform-specific. Results are
representative of three or more independent experiments.
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Figure 6. In vivo T15-IgM treatment blunts responses to TLR agonists
(A) Groups of adult C57BL/6 mice received saline, IgM control or T15-IgM, then were
challenged with agonists for TLR3 (poly I:C), TLR4 (LPS), TLR7 (SM-360320)(27), TLR9
(CpG ODN1018). After 18hr, splenic Mφ and CD11chi DC were evaluated, based on indicated
gates (left panels). Representative histograms and mean fluorescence indices (MFI) are
depicted for: top value from gray shaded area from naïve mouse; saline pretreatment then TLR
agonist challenge dark solid line; isotype control followed by TLR agonist challenge from thick
gray dashed line; bottom, T15-NAb followed by TLR agonist, black dashed line. Compared
to naïve mice, challenge with TLR agonist induces high expression levels of MHC II and CD86,
but was inhibited by T15-NAb. (B) T15-IgM or apoptotic-cell treatments inhibited poly I:C
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induced activation of splenic Mφ (F4/80+) and myeloid DC (CD11chi) from C57BL/6 mice.
Groups received buffer alone (PBS), necrotic (Necr.) thymocytes, apoptotic (Apop.)
thymocytes, isotype control (Iso IgM), T15 or the indicated combination. Results are shown
for individual mice at 18 hr after challenge. Horizontal bars depict mean values for each group.
There were no significant differences in the representation of splenic F4/80+ Mφ and
CD11chi DC between different treatment groups. (C) T15-IgM or apoptotic-cell treatments
inhibits poly I:C induction of serum levels of pro-inflammatory cytokines and chemokines in
C57BL/6 mice. P values from two-tailed t test are shown. Results were pooled from three or
more independent experiments. (D) Representative flow cytometric analyses after gating on
early apoptotic thymocytes (i.e., Annexin V+ 7AAD−) of IgM and MBL from sera of naïve
adult C57BL/6, or mice that received three weekly apoptotic cell (AC) treatments, with level
of binding shown to be dose-dependent based on the % sera. PC-BSA incubation greatly
reduced the level of MBL deposition. Representative of three independent studies.
Chen et al. Page 28
J Immunol. Author manuscript; available in PMC 2010 July 15.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 7. B-cell deficient mice are not protected by apoptotic-cell treatments
T15-IgM but not apoptotic-cell treatments inhibits poly I:C-induced activation of splenic
Mφ and myeloid DC in B-cell deficient (muMT) mice. Results are for MFI from flow cytometry
studies, as shown in Figures 6A&B. Results are for individual mice are the pooled from two
independent experiments.
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Figure 8. T15-NAb protects from inflammatory arthritis
(A) DBA/1 mice were immunized with CII and boosted on day 20. T15-NAb at 2 mg/dose,
isotype control, apoptotic thymocytes or necrotic cells (2.5 × 107) in saline, or saline alone
were administered weekly. T15-NAb and apoptotic-cell treatments significantly reduced
clinical arthritis joint scores compared to control treatments (isotype control, saline and
necrotic cells) (P<0.001 by Bonferroni test). The isotype control group was not significantly
different than saline-treated group. Data are pooled from two independent studies with separate
treatment and control groups of four mice (total N=8). Depicted are mean values+/−SEM.
(B) Protective T15-NAb reduced inflammatory cellular infiltrates in CIA. Compared to isotype
control treatment at left, T15-IgM anti-PC NAb significantly reduced cartilage and bone
destruction (arrowhead), and greatly reduced level of cellular infiltrates (arrow)(40Xmag).
Below, knees from control-treated mice had progressive pathologic changes of compromised
articular cartilage that is shown with safranin O (bright orange), while T15-IgM provided
protection from cellular infiltrates, and cartilage and bone destruction. (C) Histologic arthritis
scores are depicted for CIA treatment study, with values derived as previously described
(28). (D) To induce autoantibody-mediated arthritis, BALB/c mice received a commercial
cocktail of anti-CII antibodies, and data represent sequential measurements from two
independent studies with separate treatment and control groups of four mice (total N=8).
Weekly T15-NAb infusions significantly reduced arthritis based on clinical scores of joint
scores, compared to saline or isotype control-treated mice, with P<0.0022 at the peak d14
response. Depicted are mean values +/− SD.
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